Structured evidence table for Vitamin K1 Bone Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Vitamin K1 Bone Health Randomized Trial | Conclusion The data from this post-hoc analysis do not provide evidence for the assumption that vitamin K status modifies or enhances effects of vitamin D supplementation on cardiovascular or bone parameters. | 2 | Theiler-Schwetz V (2026) | Vitamin K status has no influence on the effect of vitamin D supplementation on bone turnover and cardiovascular markers: a randomized controlled trial. |
| Vitamin K1 Bone Health Randomized Trial | These findings are in line with current guidelines, which do not routinely recommend vitamin K and D co-treatment in patients with osteoporosis. | 2 | Theiler-Schwetz V (2026) | Vitamin K status has no influence on the effect of vitamin D supplementation on bone turnover and cardiovascular markers: a randomized controlled trial. |
| Vitamin K1 Bone Health Randomized Trial | Background/objectives Vitamin K and D co-treatment may have additive effects on bone and cardiovascular health and is frequently used as an over-the-counter supplement. | 2 | Theiler-Schwetz V (2026) | Vitamin K status has no influence on the effect of vitamin D supplementation on bone turnover and cardiovascular markers: a randomized controlled trial. |
| Vitamin K1 Bone Health Randomized Trial | The primary aim of this study was to assess whether the effect of vitamin D supplementation on bone turnover markers and cardiovascular parameters is modified according to vitamin K status at baseline (i.e., serum levels of vitamin K1, MK4 and MK7). | 2 | Theiler-Schwetz V (2026) | Vitamin K status has no influence on the effect of vitamin D supplementation on bone turnover and cardiovascular markers: a randomized controlled trial. |
| Vitamin K1 Bone Health Randomized Trial | The question is whether vitamin K supplementation meaningfully alters vascular calcification progression or cardiovascular outcomes in patients at risk, particularly those with CKD. | 3 | Brandenburg Vincent (2026) | Vitamin K and vascular calcification: from biological plausibility to clinical realism |
| Vitamin K1 Bone Health Randomized Trial | This review summarizes the current interventional evidence and discusses why initial enthusiasm should now be balanced by clinical realism. | 3 | Brandenburg Vincent (2026) | Vitamin K and vascular calcification: from biological plausibility to clinical realism |
| Vitamin K1 Bone Health Randomized Trial | Vitamin K2 refers to menaquinones, including MK-4 to MK-13, which are found in fermented foods and animal products and are also produced by bacteria. | 3 | Brandenburg Vincent (2026) | Vitamin K and vascular calcification: from biological plausibility to clinical realism |
| Vitamin K1 Bone Health Randomized Trial | Most clinicians encounter vitamin K through its function as an essential cofactor for γ-carboxylation of coagulation factors and through the clinical use of vitamin K antagonists. | 3 | Brandenburg Vincent (2026) | Vitamin K and vascular calcification: from biological plausibility to clinical realism |
Source documents